NBSE has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
NBSE has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
NeuBase Therapeutics's quarterly cash and cash equivalents increased from Mar. 2023 ($13.85 Mil) to Jun. 2023 ($14.75 Mil) but then stayed the same from Jun. 2023 ($14.75 Mil) to Sep. 2023 ($12.57 Mil).
NeuBase Therapeutics's annual cash and cash equivalents increased from Sep. 2019 ($10.31 Mil) to Sep. 2020 ($31.99 Mil) and increased from Sep. 2020 ($31.99 Mil) to Sep. 2021 ($52.89 Mil).
The historical data trend for NeuBase Therapeutics's Cash And Cash Equivalents can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.
NeuBase Therapeutics (NAS:NBSE) Cash And Cash Equivalents Explanation
A high number means either:
1) The company has competitive advantage generating lots of cash
2) Just sold a business or bonds (not necessarily good)
A low stockpile of cash usually means poor to mediocre economics.
There are 3 ways to create large cash reserve.
1) Sell new bonds or equity to public
2) Sell business or asset
3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)
When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.
Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.
Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.
Be Aware
Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.
Thank you for viewing the detailed overview of NeuBase Therapeutics's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.
Symetryx Corp | 10 percent owner | 2828 BATHURST ST #400, TORONTO A6 M6B3A7 |
Aleta Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
Barry Shiff | 10 percent owner | 461 LYTTON BLVD., TORONTO A6 M5N 1S5 |
William Roland Mann | officer: COO | 700 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Todd P. Branning | officer: Chief Financial Officer | C/O AMNEAL PHARMACEUTICLAS, INC., 400 CROSSING BOULEVARD, BRIDGEWATER NJ 08807 |
Eric I Richman | director | C/O REV CAPITAL II, LLC, 9740 SORREL AVE, POTOMAC MD 20854 |
Eric J Ende | director | C/O MATINAS BIOPHARMA HOLDINGS, INC., 1545 ROUTE 206 SOUTH, SUITE 302, BEDMINSTER NJ 07921 |
Sandra Rojas-caro | officer: Chief Medical Officer | C/O AEGLEA BIOTHERAPEUTICS, INC., 901 S. MOPAC EXPRESSWAY, STE. 250, AUSTIN TX 78746 |
Kianoush Motesharei | officer: See Remarks | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Gerald J Mcdougall | director | 350 TECHNOLOGY DRIVE, PITTSBURGH PA 15219 |
Curt Bradshaw | officer: Chief Scientific Officer | 177 E COLORADO BLVD, STE 700, PASADENA CA 91105 |
Gines Diego Miralles | director | 2235 VIA FRESCA, LA JOLLA CA 92037 |
Franklyn G Prendergast | director | |
Dietrich A Stephan | director, 10 percent owner, officer: President and CEO | 213 SMITHFIELD ST, PITTSBURGH PA 15222 |
Lipizzaner Llc | 10 percent owner | 1209 ORANGE STREET, WILMINGTON DE 19801 |
From GuruFocus
By GuruFocusNews 07-01-2022
By GuruFocusNews 06-26-2022
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.